Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 6/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538717 | 0.87 | SMN1; SMN2 (0.34) | PLK1CYP11B1CYP11B2TTKSMN1; SMN2 | |
| SCHEMBL3542245 | 0.84 | SMN1; SMN2 (0.37) | PLK1CYP11B1CYP11B2TTKSMN1; SMN2 | |
| SCHEMBL1203578 | 0.82 | SMN1; SMN2 (0.35) | PLK1CYP11B1CYP11B2TTKSMN1; SMN2 | |
| SCHEMBL3543713 | 0.80 | RAD52 (0.38) | PLK1CYP11B1CYP11B2TTKSMN1; SMN2 | |
| SCHEMBL3542184 | 0.79 | SMN1; SMN2 (0.40) | PLK1CYP11B1CYP11B2TTKSMN1; SMN2 | |
| SCHEMBL3539972 | 0.77 | PDE2A (0.33) | ABL1BCR | |
| SCHEMBL3548150 | 0.76 | RPS6KA3 (0.37) | PLK1CYP11B1CYP11B2TTKSMN1; SMN2 | |
| SCHEMBL3543954 | 0.75 | RPS6KA3 (0.45) | PLK1CYP11B1CYP11B2TTKSMN1; SMN2 | |
| SCHEMBL7747078 | 0.75 | RPS6KA3 (0.36) | SMN1; SMN2 | |
| SCHEMBL2874984 | 0.74 | RPS6KA3 (0.36) | SMN1; SMN2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | PLK1 847/4885CYP11B1 2/4885CYP11B2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.